

presentations

- 2018/jan **Pietge H**, Sanchez Velazquez P, Akhoundova D, Siebenhüner A, Winder T, Bachmann H, Nguyen TDL, Breitenstein S, Petrowsky H, Pestalozzi B, Clavien PA, Samaras P: Downstaging of unresectable intrahepatic or hilar cholangiocellular carcinoma by selective intra-arterial floxuridine and systemic cisplatin and gemcitabine. A dose finding single center phase IIa study, *Gastrointestinal Cancers Symposium, San Francisco 2018, poster presentation*
- 2015/sep **Seifert H**, Georgiou A, Alexander H, McLachlan J, Bodla S; Kaye S, Barton D, Nobbenhuis M, Gore M, Banerjee S: Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC), *European Cancer Congress, Vienna 2015, poster presentation*
- 2014/may Piperno-Neumann S, Kapiteijn E, Larkin J, Carvajal R, Luke J, **Seifert H**, Roozen I, Zoubir M, Yang L, Choudhury S, Yerramilli-Rao P, Hodi FS, Schwartz GK: Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 In patients with metastatic uveal melanoma, *ASCO, Chicago 2014, poster presentation*
- 2014/may Piperno-Neumann S, Kapiteijn E, Larkin J, Carvajal R, Luke J, **Seifert H**, Roozen I, Zoubir M, Ramkumar T, Emery C, Derti A, Yerramilli-Rao P, Hodi FS and Schwartz GK: Landscape of genetic alterations in uveal melanoma, *ASCO, Chicago 2014, poster presentation*
- 2008/oct Annual meeting of the german, swiss and austrian society of hematooncology 2008, Vienna/Austria: "Loss of 17p as an independent high risk factor in adults with acute myeloid leukemia (AML)"

publications

- 2020/aug **Pietge H**, Sanchez Velazquez P, Akhoundova D, Siebenhüner A, Winder T, Bachmann H, Nguyen TDL, Breitenstein S, Petrowsky H, Pestalozzi B, Clavien PA, Samaras P: Combination of HAI-FUDR and systemic gemcitabine and cisplatin in unresectable cholangiocellular carcinoma: A dose finding single center phase IIa study (ONK-USZ-003); *accepted for publication in Oncology*
- 2020/jan **Pietge H**, Pestalozzi B: Rheumatische Beschwerden in der Onkologie; *Rheuma Schweiz Fachzeitschrift*

- 2018/jan Siebenhüner A, **Seifert H**, Bachmann H, Seifert B, Winder T, Clavien PA, Stupp R, Knuth A, Pestalozzi B, Samaras P: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine. A prospective single center phase II study; *BMC Cancer* (2018) 18:72 DOI 10.1186/s12885-017-3967-0
- 2017/jun **Pietge H**, Rickenbacher A, Turina A, Misselwitz B: Das kolorektale Karzinom – ein klinischer Überblick; *Swiss Medical Forum*
- 2017/jun **Seifert H**, Siebenhüner A: Früherkennung Brustkrebs – Stellenwert der Screening-Mammografie anhand eines Fallbeispiels; *Praxis* 2017; 106 (14): 1–9
- 2016/apr **Seifert H**, Fisher R, Martin JM, Edmonds K, Hughes P, Kobra K, Gore M, Larkin J: Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib, *Melanoma Research*, 2016 Apr;26(2):138-44. doi: 10.1097/CMR.0000000000000218
- 2015/nov **Seifert H**, Hirata E, Sahai E, Larkin J: Extrinsic factors can mediate resistance to BRAF inhibition in CNS melanoma metastases; *Pigment Cell Melanoma Res.* 2016 Jan;29(1):92-100. doi: 10.1111/pcmr.12424. Epub 2015 Nov 3
- 2015/aug **Seifert H**, Georgiou A, Alexander H, McLachlan J, Bodla S; Kaye S, Barton D, Nobbenhuis M, Gore M, Banerjee S: Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC), *Journal of Gynecologic Oncology.* 2015 Nov;139(2):216-20. doi: 10.1016/j.ygyno.2015.08.015. Epub 2015 Aug 28
- 2015/jan Moriceau GM, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, **Seifert H**, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, and Lo RS: Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug Addiction, *Cancer Cell*, 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15
- 2013/jul **Seifert H**, Hess C, Terracciano L, Eckstein J.: „Not your usual diarrhoea: severe colonic toxicity of mycophenolate due to intestinal CMV and EBV infection“, *BMJ Case Rep.* 2013 Jul 10; 2013. pii: bcr2013009882. doi: 10.1136/bcr-2013-009882.
- 2012/dec **Seifert H**, Rothschild S: "Transient elevation of serum carcinoembryonic antigen level in a patient with hypothyroidism", case report, *MEMO* (2012) 5:269-272; DOI 10.1007/s12254-012-0056-6
- 2009/jan **Seifert H**, Mohr B, Thiede C, Oelschlägel U, Schäkel U, Illmer T, Soucek

S, Ehninger G, Schaich M: "The prognostic impact of 17p (p53) deletion in 2275 adults with acute myeloid leukemia (AML)", *Leukemia*. 2009 Apr; 23(4):656-63. Epub 2009 Jan 8